The efficacy and safety of toripalimab combined with anlotinib in the first-line treatment of Chinese patients with metastatic melanoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.9560
Abstract: 9560 Background: Acral, mucosal and non-CSD melanoma are the major subtypes in Chinese melanoma patients, with poor response to antiprogrammed cell death-1 (PD-1) monotherapy. Anti PD-1 monoclonal antibodies combined with anti-angiogenesis agent have showed synergistic… read more here.
Keywords: treatment; toripalimab combined; patients metastatic; melanoma ... See more keywords
Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
Sign Up to like & getrecommendations! Published in 2023 at "Open Life Sciences"
DOI: 10.1515/biol-2022-0606
Abstract: Targeted therapy and PD - 1/L1 inhibitors are the main treat - ments for BRAF V600 - mutated melanomas [ 1,2 ] . Recently, PD - 1 inhibitors for melanoma with toripalimab have been developed… read more here.
Keywords: vemurafenib following; toripalimab combined; toripalimab; skin toxicity ... See more keywords
Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.796407
Abstract: Urothelial carcinoma is the most common primary upper tract urinary carcinoma. If surgery, chemotherapy, and immunotherapy fail, the prognosis for upper tract urinary carcinoma is extremely poor. Immunotherapy combined with antiangiogenesis therapy is a new… read more here.
Keywords: pembrolizumab; toripalimab combined; metastatic upper; carcinoma ... See more keywords